Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics.
Dahlén B, Nizankowska E, Szczeklik A, Zetterström O, Bochenek G, Kumlin M, Mastalerz L, Pinis G, Swanson LJ, Boodhoo TI, Wright S, Dubé LM, Dahlén SE.
Dahlén B, et al. Among authors: mastalerz l.
Am J Respir Crit Care Med. 1998 Apr;157(4 Pt 1):1187-94. doi: 10.1164/ajrccm.157.4.9707089.
Am J Respir Crit Care Med. 1998.
PMID: 9563738
Clinical Trial.